Alexandria Real Estate-backed Acrivon has filed to go public while H2 Green Steel increased its corporate-backed series B round to $255m.

Public markets Acrivon Therapeutics, the US-based oncology therapy developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, has filed for an initial public offering on the Nasdaq Global Market. Its overall funding stood at over $115m as of November 2021. Reverse merger Oculis, the Switzerland-based eyesight treatment developer backed by pharmaceutical…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.